Institute for Radiological Protection and Nuclear Safety (IRSN), PSE-SANTE/SESANE/Laboratory of Epidemiology, BP 17, Fontenay-aux-Roses, 92262, France.
M3C-Necker, Hôpital universitaire Necker-Enfants malades, Université de Paris Cité, Paris, France.
Eur J Epidemiol. 2023 Jul;38(7):821-834. doi: 10.1007/s10654-023-01010-7. Epub 2023 May 16.
Pediatric patients with congenital heart disease (CHD) often undergo low dose ionizing radiation (LDIR) from cardiac catheterization (CC) for the diagnosis and/or treatment of their disease. Although radiation doses from a single CC are usually low, less is known about the long-term radiation associated cancer risks. We aimed to assess the risk of lympho-hematopoietic malignancies in pediatric CHD patients diagnosed or treated with CC. A French cohort of 17,104 children free of cancer who had undergone a first CC from 01/01/2000 to 31/12/2013, before the age of 16 was set up. The follow-up started at the date of the first recorded CC until the exit date, i.e., the date of death, the date of first cancer diagnosis, the date of the 18th birthday, or the 31/12/2015, whichever occurred first. Poisson regression was used to estimate the LDIR associated cancer risk. The median follow-up was 5.9 years, with 110,335 person-years. There were 22,227 CC procedures, yielding an individual active bone marrow (ABM) mean cumulative dose of 3.0 milligray (mGy). Thirty-eight incident lympho-hematopoietic malignancies were observed. When adjusting for attained age, gender and predisposing factors to cancer status, no increased risk was observed for lympho-hematopoietic malignancies RR = 1.00 (95% CI: 0.88; 1.10). In summary, the risk of lympho-hematopoietic malignancies and lymphoma was not associated to LDIR in pediatric patients with CHD who undergo CC. Further epidemiological studies with greater statistical power are needed to improve the assessment of the dose-risk relationship.
患有先天性心脏病 (CHD) 的儿科患者经常因心脏导管术 (CC) 的诊断和/或治疗而接受低剂量电离辐射 (LDIR)。尽管单次 CC 的辐射剂量通常较低,但对于与长期辐射相关的癌症风险知之甚少。我们旨在评估接受 CC 诊断或治疗的小儿 CHD 患者患淋巴血液恶性肿瘤的风险。建立了一个法国队列,纳入了 17104 名在 2000 年 1 月 1 日至 2013 年 12 月 31 日期间 16 岁之前接受过首次 CC 的无癌症的儿童。随访从首次记录的 CC 日期开始,直至退出日期,即死亡日期、首次癌症诊断日期、18 岁生日或 2015 年 12 月 31 日,以先到者为准。泊松回归用于估计 LDIR 相关的癌症风险。中位随访时间为 5.9 年,共 110335 人年。共进行了 22227 次 CC 手术,个体活性骨髓 (ABM) 的平均累积剂量为 3.0 毫戈瑞 (mGy)。观察到 38 例新发淋巴血液恶性肿瘤。在校正了达到的年龄、性别和癌症状态的易患因素后,未观察到淋巴血液恶性肿瘤的风险增加 (RR = 1.00,95%CI:0.88;1.10)。总之,在接受 CC 的 CHD 儿科患者中,淋巴血液恶性肿瘤和淋巴瘤的风险与 LDIR 无关。需要具有更大统计能力的进一步流行病学研究来改善剂量-风险关系的评估。